Antibiotic substance produced by various Streptomyces species. It is an inhibitor of enzymatic activities that involve glutamine and is used as an antineoplastic and immunosuppressive agent.
An enzyme that catalyzes the synthesis of fructose-6-phosphate plus GLUTAMINE from GLUTAMATE plus glucosamine-6-phosphate.
Hexosamines are a type of sugar found in the human body that are involved in the formation of glycosaminoglycans, which play a role in various biological processes such as cell signaling and inflammation.
An amino acid that inhibits phosphate-activated glutaminase and interferes with glutamine metabolism. It is an antineoplastic antibiotic produced by an unidentified species of Streptomyces from Peruvian soil. (From Merck Index, 11th ed)
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.
A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.

Regulation of de novo purine biosynthesis in human lymphoblasts. Coordinate control of proximal (rate-determining) steps and the inosinic acid branch point. (1/103)

Purine nucleotide synthesis de novo has been studied in a permanent tissue culture line of human splenic lymphoblasts with particular attention to coordination of control of the proximal (rate-determining) steps with the distal branch point of the pathway. An assay was used which permits simultaneous determination of the overall rate of labeling of all intracellular purines with sodium [14C]formate, as well as the distribution of isotope into all intracellular guanine- and adenine-containing compounds. The guanine to adenine labeling ratio was used as an index of IMP branch point regulation. It was found that exogenous adenine and guanine produce feedback-controlling effects not only on the first step in the de novo pathway, but also on the IMP branch point. Concentrations of adenine which produce less than 40% inhibition of the overall rate of de novo purine synthesis do so by selectively inhibiting adenine nucleotide synthesis de novo by 50 to 70% while stimulating guanine nucleotide synthesis de novo by up to 20%. A reciprocal effect is seen with exogenous guanine. The adenosine analog 6-methylmercaptopurine ribonucleoside selectivity inhibits adenine nucleotide synthesis via the de novo pathway but not from exogenous hypoxanthine. Thus, the reactions of purine nucleotide interconversion, in particular adenylosuccinate synthetase, may be regulated differently in cells deriving their purine nucleotides solely from de novo synthesis than when deriving them via "salvage" of preformed hypoxanthine.  (+info)

The cytotoxicity of DNA carboxymethylation and methylation by the model carboxymethylating agent azaserine in human cells. (2/103)

Carboxymethylating agents are potential sources of endogenous DNA damage that have been proposed as possible contributors to gastrointestinal carcinogenesis. The cytotoxicity of the model DNA carboxymethylating agent azaserine was investigated in human cells. Expression of the DNA repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) did not affect sensitivity to the drug in two related Raji Burkitt's lymphoma cell lines. DNA mismatch repair-defective variants of Raji cells which display increased tolerance to DNA methylation damage were not selectively resistant to azaserine. Complementary results were obtained with a second carboxymethylating agent, potassium diazoacetate. In contrast, lymphoblastoid cell lines representative of each of the xeroderma pigmentosum complementation groups, including the variant, were all significantly more sensitive to azaserine than nucleotide excision repair-proficient cells. The hypersensitivity of XP cells was not due to systematic differences in the concentrations of intracellular thiol compounds or related thiol metabolizing enzymes. The data indicate that of the two types of potentially lethal DNA damage which azaserine introduces, carboxymethylated bases and O(6)-methylguanine, the former are repaired by nucleotide excision repair and are a more significant contributor to azaserine lethality in human cells.  (+info)

Regulation of insulin-stimulated glucose transport by chronic glucose exposure in 3T3-L1 adipocytes. (3/103)

Chronic hyperglycemia causes insulin resistance, termed glucose toxicity. Herein we studied chronic glucose-dependent regulation of the glucose transport system in adipocytes. 3T3-L1 adipocytes were incubated for up to 24 h with low (1 mM) or high (25 mM) glucose, and glucose transport was subsequently analyzed. 100 nM insulin was present throughout the experiments. 24 h incubation with 1 mM glucose caused a 2.3+/-0.4 fold increase in glucose transport activity, compared to the values obtained with 25 mM glucose. This difference was not observed when 24 h incubation was carried out without insulin. Glucose transport activity was not increased at 3 or 6 h incubation with 1 mM glucose, but was increased at 12 h, which closely paralleled increased expression of GLUT1. In addition to increased GLUT1 expression, more efficient translocation of GLUT1 to the plasma membrane was observed when incubated with 1 mM glucose compared to 25 mM glucose. The addition of azaserin or deprivation of glutamine at 25 mM glucose did not increase the glucose transport activity to the level obtained with 1 mM glucose. PD98059 did not affect glucose transport activity when incubated with 1 mM or 25 mM glucose. In conclusion, the present study is the first to show that, in 3T3-L1 adipocytes, chronic exposure to low (1 mM) and high (25 mM) glucose leads to different insulin-stimulated glucose transport activities. These differences result from the difference in the expression and plasma membrane distribution of GLUT1, but not of GLUT4, and the hexosamine biosynthesis pathway or extracellular signal-regulated protein kinase is not involved.  (+info)

Cellular autophagic capacity is highly increased in azaserine-induced premalignant atypical acinar nodule cells. (4/103)

Although cellular autophagy is recognized as a major pathway of macromolecular catabolism, little data are available regarding its activity or regulation in tumor cells. We approach this problem by morphometrical investigation into the possible changes in autophagic activity during progression of rat pancreatic adenocarcinoma induced by azaserine and promoted by a raw soya flour-containing pancreatotrophic diet. In the present study, the autophagic capacity of the carcinogen-induced premalignant atypical acinar nodule cells was characterized and compared with controls (normal tissue of rats kept on standard laboratory or pancreatotrophic diet and host tissue of the premalignant nodules of the azaserine-treated rats). Given for 90 min, vinblastine, an enhancer of autophagic segregation (i.e. formation of autophagic vacuoles), caused a one to two orders of magnitude larger expansion of the autophagic compartment in atypical nodule cells than in the controls. Then a 20 min blockade of segregation by cycloheximide led to regression of the autophagic compartment, which was barely measurable or moderate in the controls but exceeded 50% in the premalignant cells. At the same time, the cytoplasmic volume fraction of early autophagic vacuoles regressed to a near zero value in each cell type. Expansion and regression rates of these nascent vacuoles showed that both segregation and degradation were 6-20 times faster in the nodule than in normal tissue cells. These results show that the autophagic capacity of the premalignant cells in our system is greatly increased, possibly making these cells unusually sensitive to up-regulation of their self-digesting activity in response to different extracellular signals or drugs.  (+info)

Role of the basic helix-loop-helix transcription factor p48 in the differentiation phenotype of exocrine pancreas cancer cells. (5/103)

The majority of human pancreatic adenocarcinomas display a ductal phenotype; experimental studies indicate that tumors with this phenotype can arise from both acinar and ductal cells. In normal pancreas acinar cells, the pancreas transcription factor 1 transcriptional complex is required for gene expression. Pancreas transcription factor 1 is a heterooligomer of pancreas-specific (p48) and ubiquitous (p75/E2A and p64/HEB) basic helix-loop-helix proteins. We have examined the role of p48 in the phenotype of azaserine-induced rat DSL6 tumors and cancers of the human exocrine pancreas. Serially transplanted acinar DSL6 tumors express p48 whereas DSL6-derived cell lines, and the tumors induced by them, display a ductal phenotype and lack p48. In human pancreas cancer cell lines and tissues, p48 is present in acinar tumors but not in ductal tumors. Transfection of ductal pancreas cancers with p48 cDNA did not activate the expression of amylase nor a reporter gene under the control of the rat elastase promoter. In some cell lines, p48 was detected in the nucleus whereas in others it was cytoplasmic, as in one human acinar tumor. Together with prior work, our findings indicate that p48 is associated with the acinar phenotype of exocrine pancreas cancers and it is necessary, but not sufficient, for the expression of the acinar phenotype.  (+info)

Biallelic methylation and silencing of mouse Aprt in normal kidney cells. (6/103)

Heritable gene silencing is an important mechanism of tumor suppressor gene inactivation in a variety of human cancers. In the present study, we show that methylation-associated silencing of the autosomal adenine phosphoribosyltransferase (Aprt) locus occurs in primary mouse kidney cells. Aprt-deficient cells were isolated from mice that were heterozygous for Aprt, i.e., they contained one wild-type Aprt allele and one targeted allele bearing an insertion of the bacterial neo gene. Although silencing of the wild-type allele alone was sufficient for the cells to become completely Aprt-deficient, biallelic methylation of the promoter region was found to occur. Moreover, despite the absence of selective pressure against the targeted allele, phenotypic silencing of the inserted neo gene accompanied silencing of the wild-type Aprt allele. A potential role for allelic homology in these events is discussed.  (+info)

Sterol regulatory element-binding protein-1 is regulated by glucose at the transcriptional level. (7/103)

In vivo studies suggest that sterol regulatory element-binding protein (SREBP)-1 plays a key role in the up-regulation of lipogenic genes in the livers of animals that have consumed excess amounts of carbohydrates. In light of this, we sought to use an established mouse hepatocyte cell line, H2-35, to further define the mechanism by which glucose regulates nuclear SREBP-1 levels. First, we show that these cells transcribe high levels of SREBP-1c that are increased 4-fold upon differentiation from a prehepatocyte to a hepatocyte phenotype, making them an ideal cell culture model for the study of SREBP-1c induction. Second, we demonstrate that the presence of precursor and mature forms of SREBP-1 protein are positively regulated by medium glucose concentrations ranging from 5. 5 to 25 mm and are also regulated by insulin, with the amount of insulin in the fetal bovine serum being sufficient for maximal stimulation of SREBP-1 expression. Third, we show that the increase in SREBP-1 protein is due to an increase in SREBP-1 mRNA. Reporter gene analysis of the SREBP-1c promoter demonstrated a glucose-dependent induction of transcription. In contrast, expression of a fixed amount of the precursor form of SREBP-1c protein showed that glucose does not influence its cleavage. Fourth, we demonstrate that the glucose induction of SREBP could not be reproduced by fructose, xylose, or galactose nor by glucose analogs 2-deoxy glucose and 3-O-methyl glucopyranose. These data provide strong evidence for the induction of SREBP-1c mRNA by glucose leading to increased mature protein in the nucleus, thus providing a potential mechanism for the up-regulation of lipogenic genes by glucose in vivo.  (+info)

Adenocarcinoma of the pancreas in azaserine-treated rats. (8/103)

Development of a model of carcinoma of the pancreas in rats was approached by attempting to identify chemicals that (a) behave as mutagens and (b) localize in the pancreas following systemic administration; and then to study the effects of long-term administration. Azaserine was selected because it behaves as a direct-acting mutagen in two bacterial test systems and because tissue distribution studies showed concentration especially in kidney and pancreas. Groups of rats have been given i.p. injections once or twice weekly for 6 months, and rats have been autopsied after 6 to 18 months. During the first year pancreases developed (a) nodules of atypical exocrine cells which seem to represent hyperplastic foci and (b) encapsulated adenomas. After 1 year most pancreases from treated rats are diffusely abnormal and contain many hyperplastic nodules and adenomas, while more than one-quarter have had pancreatic adenocarcimona. Metastases have been observed in lymph nodes, liver, and lung. No carcinomas or adenomas have been observed in control rats. No other organ shows as high an incidence of involvement as pancreas, but renal neoplasms were frequent. Studies with another chemical O-(N-methyl-N-nitroso-beta-alanyl)-L-serine, are at an earlier stage. The tissue distribution of radioactivity following injection of a 14C-labeled sample is similar to that of azaserine; however, this compound is not a direct-acting bacterial mutagen. Rats treated for 6 months twice weekly i.p. have a higher incidence of nodules of atypical acinar cells than did controls, although the number of nodules per rat is few. No adenomas or carcinomas have been found during 13 months of the study. We conclude that azaserine is a carcinogen in rats and causes major abnormalities of growth and differentiation of the exocrine pancreas, including adenocarcinoma in some rats. O-(N-Methyl-N-mitroso-beta-alanyl)-L-serine had less effect than azaserine on pancreatic growth and differentiation.  (+info)

Azaserine is a chemical compound that is used as a nitrogen mustard agent in chemotherapy. It is a prodrug that is converted to its active form, mustard gas, in the body. Mustard gas is a toxic chemical that can cause severe skin and lung damage, as well as other health problems. Azaserine is typically used to treat certain types of cancer, such as Hodgkin's lymphoma and non-Hodgkin's lymphoma. It is usually given in combination with other chemotherapy drugs to increase its effectiveness.

Hexosamines are a type of sugar molecule that are found in the human body. They are composed of a hexose (a sugar with six carbon atoms) and an amine group. Hexosamines are important components of the glycosaminoglycan (GAG) molecules that are found in the extracellular matrix of connective tissue. GAGs are complex carbohydrates that play a variety of roles in the body, including providing structural support to tissues, regulating cell signaling, and participating in the immune response. Hexosamines are also found in other types of molecules, such as glycoproteins and proteoglycans. In the medical field, hexosamines are of interest because they have been implicated in a number of diseases, including cancer, diabetes, and inflammatory disorders.

Diazooxonorleucine (DZNLE) is a synthetic amino acid that has been used in the medical field as a radiolabeling agent for imaging studies. It is a modified form of leucine, with the side chain replaced by a diazo group and an oxygen atom. When DZNLE is administered to a patient, it is taken up by cells in the body and incorporated into proteins, where it can be detected using imaging techniques such as positron emission tomography (PET). This allows doctors to visualize and study the function of specific organs or tissues, such as the brain or the heart. DZNLE has been used in research studies to investigate a variety of conditions, including cancer, neurodegenerative diseases, and infectious diseases. It has also been used as a diagnostic tool to help identify and monitor the progression of certain diseases.

Glutamine is an amino acid that plays a crucial role in various physiological processes in the body. It is one of the most abundant amino acids in the human body and is involved in a wide range of functions, including: 1. Energy production: Glutamine is a major source of fuel for cells in the body, particularly in the muscles and immune system. 2. Protein synthesis: Glutamine is a key building block for proteins and is essential for the growth and repair of tissues. 3. Immune function: Glutamine plays a critical role in the function of the immune system, particularly in the production of white blood cells. 4. Gut health: Glutamine is important for maintaining the health of the gut lining and preventing damage to the gut. In the medical field, glutamine is often used as a supplement to support various health conditions, including: 1. Wound healing: Glutamine has been shown to promote wound healing and reduce the risk of infection. 2. Cancer treatment: Glutamine supplementation may help to reduce the side effects of cancer treatment, such as fatigue and muscle wasting. 3. Immune system support: Glutamine supplementation may help to boost the immune system and reduce the risk of infections. 4. Digestive disorders: Glutamine may be helpful in treating digestive disorders such as inflammatory bowel disease and irritable bowel syndrome. Overall, glutamine is an important nutrient that plays a crucial role in many physiological processes in the body and may be beneficial in supporting various health conditions.

... has a solubility of 50 mg/mL in water, a melting point of 146-162 °C, a vapor pressure of 1.53x10−10mmHg at 25 °C, ... Azaserine also downregulates the expression of VCAM-1 and ICAM-1 in response to TNF-α, and research indicates that it may have ... Azaserine inhibits the rate limiting step of the metabolic hexosamine pathway and irreversibly inhibits γ-glutamyltransferase ... Azaserine is a naturally occurring serine derivative diazo compound with antineoplastic and antibiotic properties deriving from ...
... produces the antibiotic azaserine. List of Streptomyces species LPSN bacterio.net Deutsche Sammlung von ...
1993). "Effects of the purine biosynthesis pathway inhibitors azaserine, hadacidin, and mycophenolic acid on the developing ...
For instance, glutamine analogues azaserine and 6-diazo-5-oxo-L-norleucine (DON) can inhibit GFAT, though these molecules may ...
... azaserine MeSH D12.125.837.150 - cycloserine MeSH D12.125.837.225 - droxidopa MeSH D12.125.837.300 - enterobactin MeSH D12.125. ...
Azasan azaserine (INN) azasetron (INN) azaspirium chloride (INN) azastene (INN) azatadine (INN) azatepa (INN) azathioprine (INN ...
search help, coriell offers, cell line, cell collection, institute, scientists, cell culture, coriell, biobank, research, dna, cell, search, services, help, allen, nih, ninds, nigms
In vivo sensitivity of normal and neoplastic mouse tissues to azaserine. Cancer Res. 1957; 17:804-808. ... and azaserine, the inhibitors of GFAT1, inhibited cancer cell growth [16], suggesting a potential role of GFAT in driving ...
6. AZASERINE [ԱԶԱՍԵՐԻՆ] 21. AZOCINES [ԱԶՈՑԻՆՆԵՐ] 7. AZASTEROIDS [ԱԶԱՍՏԵՐՈԻԴՆԵՐ] 22. AZOLES [ԱԶՈԼՆԵՐ] ...
The kinetics of azaserine and phosphinothricin inhibition of glutamate synthase cycle enzymes from barley leaves. A - Papers ... The kinetics of azaserine and phosphinothricin inhibition of glutamate synthase cycle enzymes from barley leaves. Plant ...
It may be worth noting that azaserine has no inhibitory effect on the conversion of b-aminolevulinic acid to heme. ...
Contribution: Chemical mechanism of O6-carboxymethyldeoxyguanine formation from azaserine and abundance in cells ...
Azaserine-induced pancreatic carcinogenesis in rats: Promotion by a diet rich in saturated fat and inhibition by a standard ... The role of cholecystokinin in dietary fat-promoted pancreatic carcinogenesis was investigated in azaserine-treated rats, using ... Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats ...
The α-diazoester azaserine was produced by expressing a biosynthetic gene cluster in Streptomyces albus. The intracellularly ... produced azaserine was used as a carbene donor to cyclopropanate another intracellularly produced molecule-styrene. The ...
Avipoxvirus B4.909.204.783.160.100 Avoidance Learning F2.463.785.373.173 Avulavirus B4.909.777.455.600.650.70 Azaserine D12.125 ... Avipoxvirus B4.909.204.783.160.100 Avoidance Learning F2.463.785.373.173 Avulavirus B4.909.777.455.600.650.70 Azaserine D12.125 ... Avipoxvirus B4.909.204.783.160.100 Avoidance Learning F2.463.785.373.173 Avulavirus B4.909.777.455.600.650.70 Azaserine D12.125 ... Avipoxvirus B4.909.204.783.160.100 Avoidance Learning F2.463.785.373.173 Avulavirus B4.909.777.455.600.650.70 Azaserine D12.125 ...
3) Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D- ...
Glutamine analogs like azaserine (Aza) and 6-diazo-5-oxo-L-norleucine (DON) can inhibit the HBP and show anti-tumor activity in ... are reduced following Azaserine (a glutamine analog and GFAT1 inhibitor) treatment as well as glucose deprivation, and this ...
Azaserine,Azathioprine,Azathioprine,Azobenzene, Barbiturates,Beclomethasone dipropionate,Benomyl,Benthiavalicarb-isopropyl,Benz ...
Azaserine), a glutamine analog that inhibits GFAT, and the GFAT inhibitor 6diazo-five-oxo-norleucine (DON) were from Sigma (St ...
Azaserine D12.125.837.75 D12.125.154.800.500 Azithromycin D2.540.505.250.50 D2.540.576.500.992.50 B-Cell Activating Factor ...
Azaserine D12.125.837.75 D12.125.154.800.500 Azithromycin D2.540.505.250.50 D2.540.576.500.992.50 B-Cell Activating Factor ...
Azaserine D12.125.837.75 D12.125.154.800.500 Azithromycin D2.540.505.250.50 D2.540.576.500.992.50 B-Cell Activating Factor ...
Azaserine D12.125.837.75 D12.125.154.800.500 Azithromycin D2.540.505.250.50 D2.540.576.500.992.50 B-Cell Activating Factor ...
","grey",0 20118,"Azaserine","115-02-6","C115026","cheminventory_bottle,cheminventory_sample,epa:all_plated,tox21:all_plated, ...
Azaserine D12.125.837.75 D12.125.154.800.500 Azithromycin D2.540.505.250.50 D2.540.576.500.992.50 B-Cell Activating Factor ...
O-Diazoacetyl-L-serine use Azaserine o-Dihydroxybenzenes use Catechols O-Ethyl-O-(4-nitrophenyl)phenylphosphonothioate use ...
... serine synthesis indicates a stepwise oxidation strategy to generate the α-diazo ester moiety of azaserine ... serine synthesis indicates a stepwise oxidation strategy to generate the α-diazo ester moiety of azaserine ...
... the acinar cells of the pancreas of rats have been induced by several systemically administered carcinogens including azaserine ... Azaserine and MNCO have induced acinar cell carcinomas in rats. Those induced by azaserine have exhibited a broad spectrum of ... Lesions induced in rodent pancreas by azaserine and other pancreatic carcinogens.. *D S Longnecker ... the acinar cells of the pancreas of rats have been induced by several systemically administered carcinogens including azaserine ...
L-asparaginase (NSC-109229) plus azaserine (NSC-742) in acute lymphatic leukemia B G Leventhal, R T Skeel, R A Yankee, E S ... L-asparaginase (NSC-109229) plus azaserine (NSC-742) in acute lymphatic leukemia B G Leventhal et al. Cancer Chemother Rep. ... plus azaserine (NSC-742) in acute lymphatic leukemia ...
L-asparaginase (NSC-109229) plus azaserine (NSC-742) in acute lymphatic leukemia B G Leventhal, R T Skeel, R A Yankee, E S ... L-asparaginase (NSC-109229) plus azaserine (NSC-742) in acute lymphatic leukemia B G Leventhal et al. Cancer Chemother Rep. ... plus azaserine (NSC-742) in acute lymphatic leukemia ...
Azaserine . . . that didnt do anything by itself, but in combination, Chester Stock showed that it was definitely active in ... So I thought, well, the first thing we did in leukemia group A was to try 6‑mercaptopurine and azaserine in a randomized trial ... I remember, my first study, I had a patient who was treated with 6-mercaptopurine and a glutamine antagonist called azaserine. ... We worked on mercaptopurine, methotrexate, and azaserine, so we knew how each one worked. ...
6. Gastrin receptor expression during azaserine-induced rat pancreatic carcinogenesis.. Tsuei BJ; Povoski SP; Zhou W; Bell RH. ... Stimulation of growth of azaserine-induced putative preneoplastic lesions in rat pancreas is mediated specifically by way of ... 3. Temporal expression of the gastrin (CCK-B) receptor during azaserine-induced pancreatic carcinogenesis.. Povoski SP; Zhou W ... 9. Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas.. Bell RH; Kuhlmann ET; ...
Azaserine,modify,26-JAN-07,(null),(null) C992,Monobenzone,modify,26-JAN-07,(null),(null) C414,Danazol,modify,26-JAN-07,(null),( ...
Figure 1. Locomotion assay to identify drugs that rescue the scn1Lab mutant epilepsy phenotype. a, Schematic of the phenotype-based screening process. Chemical libraries can be coded and aliquoted in small volumes (75 µL) into individual wells containing one mutant fish. The 96-well microplate is arranged so that six fish are tested per drug; with one row of six fish maintained as an internal control (red circles) on each plate. b, Representative images for WT and scn1Lab mutant zebrafish larvae at 5 dpf. Note the morphological similarity but darker pigmentation in mutant larvae. c, Box plot of mean velocity (in millimeters per second) for two consecutive recordings of mutant larvae in embryo media. Experiments were performed by first placing the mutant larvae in embryo media and obtaining a baseline locomotion response; embryo media was then replaced with new embryo media (to mimic the procedure used for test compounds), and a second locomotion response was obtained. The percentage change in ...
3 IARC Vol 1-125 115-02-6 Azaserine DTXSID9020118 N[C@@H](COC(=O)C=[N+]=[N-])C(O)=O MZZGOOYMKKIOOX-VKHMYHEASA-N NC(COC(=O)C=[N+ ...
Azaserine Preferred Term Term UI T004033. Date01/01/1999. LexicalTag NON. ThesaurusID ... Azaserine Preferred Concept UI. M0002063. Registry Number. 87299V3Q9W. Related Numbers. 115-02-6. Scope Note. Antibiotic ... Azaserine. Tree Number(s). D12.125.154.800.500. Unique ID. D001377. RDF Unique Identifier. http://id.nlm.nih.gov/mesh/D001377 ...
Azaserine Preferred Term Term UI T004033. Date01/01/1999. LexicalTag NON. ThesaurusID ... Azaserine Preferred Concept UI. M0002063. Registry Number. 87299V3Q9W. Related Numbers. 115-02-6. Scope Note. Antibiotic ... Azaserine. Tree Number(s). D12.125.154.800.500. Unique ID. D001377. RDF Unique Identifier. http://id.nlm.nih.gov/mesh/D001377 ...
It was previously found that the growth of polymerase η-deficient human cells was inhibited by treatment with azaserine, a DNA ... carboxymethylation agent, suggesting the importance of this polymerase in bypassing the azaserine-induced carboxymethylated DNA ...
Azaserine - Preferred Concept UI. M0002063. Scope note. Antibiotic substance produced by various Streptomyces species. It is an ...
No azaserine ever arrived from Halvorson. I sent W-1895 to Milan, and Pischer-Fantuzzi just confirmed its sefe arrival, What do ...
5y8x (Ca: 3) - Crystal Structure of Bacillus Licheniformis Gamma Glutamyl Transpeptidase with Azaserine ...
The α-diazoester azaserine was produced by expressing a biosynthetic gene cluster in Streptomyces albus. The intracellularly ... produced azaserine was used as a carbene donor to cyclopropanate another intracellularly produced molecule-styrene. The ...
Wei, Z. - W. ; Niikura, H. ; Wang, M. ; Ryan, K. S. Identification Of The Azaserine Biosynthetic Gene Cluster Implicates ...
At the Level of the CEO-TMT Interface: download organic, Cognition, and Information ProcessingThe vivo unique azaserine on the ...
Azaserine D12.125.837.75 D12.125.154.800.500 Azithromycin D2.540.505.250.50 D2.540.576.500.992.50 B-Cell Activating Factor ...
Azaserine D12.125.837.75 D12.125.154.800.500 Azithromycin D2.540.505.250.50 D2.540.576.500.992.50 B-Cell Activating Factor ...
3 IARC Vol 1-125 115-02-6 Azaserine DTXSID9020118 N[C@@H](COC(=O)C=[N+]=[N-])C(O)=O MZZGOOYMKKIOOX-VKHMYHEASA-N NC(COC(=O)C=[N+ ...
Azaserine D12.125.837.75 D12.125.154.800.500 Azithromycin D2.540.505.250.50 D2.540.576.500.992.50 B-Cell Activating Factor ...
Azaserine D12.125.837.75 D12.125.154.800.500 Azithromycin D2.540.505.250.50 D2.540.576.500.992.50 B-Cell Activating Factor ...
Azaserine D12.125.837.75 D12.125.154.800.500 Azithromycin D2.540.505.250.50 D2.540.576.500.992.50 B-Cell Activating Factor ...
  • Azaserine is a naturally occurring serine derivative diazo compound with antineoplastic and antibiotic properties deriving from its action as a purinergic antagonist and structural similarity to glutamine. (wikipedia.org)
  • Azaserine acts by competitively inhibiting glutamine amidotransferase, a key enzyme responsible for glutamine metabolism. (wikipedia.org)
  • Lesions induced in rodent pancreas by azaserine and other pancreatic carcinogens. (nih.gov)
  • 1. Overexpression of messenger RNA for cholecystokinin-A receptor and novel expression of messenger RNA for gastrin (cholecystokinin-B) receptor in azaserine-induced rat pancreatic carcinoma. (nih.gov)
  • 2. Novel expression of gastrin (cholecystokinin-B) receptors in azaserine-induced rat pancreatic carcinoma: receptor determination and characterization. (nih.gov)
  • 3. Temporal expression of the gastrin (CCK-B) receptor during azaserine-induced pancreatic carcinogenesis. (nih.gov)
  • 5. Autoradiographic localization of cholecystokinin (CCK) receptor expression during the development of azaserine-induced rat pancreatic carcinoma. (nih.gov)
  • 6. Gastrin receptor expression during azaserine-induced rat pancreatic carcinogenesis. (nih.gov)
  • 10. Stimulation of growth of azaserine-induced putative preneoplastic lesions in rat pancreas is mediated specifically by way of cholecystokinin-A receptors. (nih.gov)
  • It was previously found that the growth of polymerase η-deficient human cells was inhibited by treatment with azaserine, a DNA carboxymethylation agent, suggesting the importance of this polymerase in bypassing the azaserine-induced carboxymethylated DNA lesions. (nih.gov)
  • Focal proliferative changes in the acinar cells of the pancreas of rats have been induced by several systemically administered carcinogens including azaserine, N-nitrosobis(2-oxopropyl)amine, N-nitroso-(2-hydroxypropyl) (2-oxopropyl)amine, and N delta-(N-methyl-N-nitrosocarbamoyl)-L-ornithine (MNCO). (nih.gov)
  • 9. Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas. (nih.gov)
  • Azaserine also downregulates the expression of VCAM-1 and ICAM-1 in response to TNF-α, and research indicates that it may have potential in identifying the L-leucine-favoring system transporter in human T-lymphocytes. (wikipedia.org)